ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing

Hodgkin lymphoma (HL) resistant to conventional therapies is increasing, making of interest the search for new schemes of treatment. Members of the “A Disintegrin And Metalloproteases” (ADAMs) family, mainly ADAM10 or ADAM17, have been proposed as therapeutic targets in solid tumors and some ADAMs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zocchi, Maria Raffaella, Camodeca, Caterina, Nuti, Elisa, Rossello, Armando, Venè, Roberta, Tosetti, Francesca, Dapino, Irene, Costa, Delfina, Musso, Alessandra, Poggi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910733/
https://www.ncbi.nlm.nih.gov/pubmed/27467923
http://dx.doi.org/10.1080/2162402X.2015.1123367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910733/
https://www.ncbi.nlm.nih.gov/pubmed/27467923
http://dx.doi.org/10.1080/2162402X.2015.1123367

Ejemplares similares